Evidence map›Paper›PMID 25298290›Full record

ArticleThe Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics2014

Patents and genome-wide DNA sequence analysis: is it safe to go into the human genome?

Robert Cook-Deegan, Subhashini Chandrasekharan

Abstract readLegal Case
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert Cook-DeeganResearch Professor of Public Policy, Internal Medicine, and Biology. He is the director of the Center for Public Genomics, a Center for Excellence in Ethical Research.
Subhashini Chandrasekharan

Funding

The Management and Organization Core will be administered by the Center for GenomP50HG003391 · NHGRI · DUKE UNIVERSITY · PI BESKOW, LAURA M. · 2004 to 2014
$9.9M
Clinical Integration of Whole Genome Sequencing: A Policy AnalysisR01HG006460 · NHGRI · JOHNS HOPKINS UNIVERSITY · PI MCGUIRE, AMY L · 2012 to 2015
$1.8M
NHGRI NIH HHS P50 HG003391NHGRI NIH HHS P50HG03391NHGRI NIH HHS R01 HG006460NHGRI NIH HHS R01HG006460
6 · The paper itself

Abstract

Some claims in patents on individual genes and methods of detecting variations appear to be infringed by whole-genome and all-exome sequencing and genomic analysis. But what is the real risk of infringement liability? The risk is probably low. This is partly because it will rarely make sense to sue, but also because the patent-holder may well lose if they do sue. Courts have recently narrowed standards of patentable subject matter, invalidating broad method claims and DNA-based claims for sequences that would be found in nature. Moreover, claims broad enough to cover WGS are likely to be invalid on other grounds, and not worth risking a lawsuit to enforce.

Indexed as

Genome, HumanHigh-Throughput Nucleotide SequencingSequence Analysis, DNAHumansPatents as TopicUnited States

Identifiers

PMID25298290
PMCPMC4281033

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.